Firestormm
Senior Member
- Messages
- 5,055
- Location
- Cornwall England
I picked this up this morning. It's an essay from 2012 only now available I believe in full. It made me wonder if, as when the NICE Guideline Development Group for example found the CCC to be inadequate on the grounds of methodology, this might also be something we would have to overcome in order that the CCC were adopted - in whatever manner - by IOM.
British Medical Journal
Neuropsychiatry
Patient Choice
Review
Unity of opposites? Chronic fatigue syndrome and the challenge of divergent perspectives in guideline development
Extracts:
There is more to read and I think it is important - if we had had time - to try and address some of these issues. Because the IOM committee will I am sure take such criticisms into account. And not all of them are without merit I don't believe.
However, whilst I think at the end of the day, the IOM are more likely to return a definition and written language more akin to the NICE Guideline (which is not all bad in my opinion), I still think the CCC personally is worth fighting for; but I also think there are aspects to it that could have been better addressed over all of these years: namely taking it into the field and validating it as a clinical definition and overcoming these objections.
If we had had the time and the ability, this kind of critique of our criteria/definitions would have been something worth doing ourselves I think. We need to acknowledge the weaknesses as well as champion the strengths and science and medicine simply have fallen short of doing the business and will continue to do so until such time as clear biomarkers can be established and we really know what we are dealing with. A critical appraisal of all the definitions/criteria/research would have been ideal - but as patients we can only do so much and I am out of my depth...
British Medical Journal
Neuropsychiatry
Patient Choice
Review
Unity of opposites? Chronic fatigue syndrome and the challenge of divergent perspectives in guideline development
Extracts:
The first example of this is in the area of diagnosis. The ScotPHN report has recommended that Scotland uses two separate categories for diagnosis, one diagnosis of ME/CFS, based on the National Institute for Health and Clinical Excellence (NICE) 2007 criteria, and a separate diagnosis of ME, based on the Canadian Consensus Document Criteria.2
They suggest that this is ‘a pragmatic approach to allow clinicians to adopt an approach to diagnosis that can ensure that those individuals for whom CFS exists are identified as rapidly as possible and also allow for more focussed assessment and review to confirm a diagnosis of ME’.2
They continue to simply state ‘Diagnostic issues are more fully explored in the Scottish Good Practice Statement (SGPS) on ME-CFS’.2 The report outlines with respect to the Canadian guidelines that it ‘emphasises the neurological features of the condition and the post-exertion fatigue/malaise which more psychiatrically-based definitions under emphasise’.2
The Canadian consensus document was originally developed in response to pressure from the National ME/FM Action Network of Canada. This patient group had disseminated a questionnaire to doctors in Canada and found that the responding doctors felt clearer clinical definitions as well as diagnostic and treatment protocols would be useful to help manage their patients with ME/CFS.
The patient group approached the then Minister of Health who then approached Health Canada to oversee a consensus document to address this.
The report states that Health Canada selected an Expert Consensus Panel for ME/CFS, and some criteria regarding nominations and experience were recommended; however, although the panel members fulfilled these criteria, they consisted of clinicians specifically selected by the patient group.4 Importantly, it was made clear that the members of the panel had complete autonomy over their consensus document.
There are many general problems with the Canadian consensus document that we could discuss, arguably the most important of which is that the guidelines were developed without reference to any standard methodology that would usually be utilised for guideline development.
The document was published in a journal that is no longer in existence, and the group who developed the guideline declare that they were in part funded by Biovail Pharmaceuticals, subsequently merged with Valeant Pharmaceuticals International, a firm that specialises in neurological and central nervous system drug development and production.5
The criteria that the Canadian consensus group have produced have not been operationally defined or validated.4 Many of the recommendations and assertions that are made in the document are not supported by published or peer-reviewed evidence, and the report holds an open stance of a neurological view of ME/CFS, also not referenced or supported by the evidence.
The document itself seems to have fallen foul of the key to guideline development in that there is a lack of robust peer review. The process of developing this document is in itself flawed, a result of patient group pressure on politicians who then outsource the work to a panel the patient group select, leading to a one-sided document.
Besides the questionable practicality of using two separate definitions for CFS and ME, it is true that there is a major discrepancy in the neurological criteria that the Canadian criteria and NICE have recommended, with the NICE guidelines referring to ‘cognitive dysfunction, such as difficulty thinking, inability to concentrate, impairment of short term memory, and difficulties word finding, planning/organising thoughts and information processing’6 they also recognise ‘dizziness and/or nausea’6 as possible symptoms.
The Canadian guidelines include in their section on ‘Neurological/cognitive manifestations…confusion, disorientation, inability to focus vision…photophobia’4 and also state that ‘Ataxia, muscle weakness and fasciculations are common’.4
The ScotPHN report makes a note following their recommendation to use the Canadian consensus criteria that ‘The HCNA acknowledges that the SGPS is the recognised clinical guidance on the diagnostic approach to ME-CFS. This is important as the SGPS also addresses the concerns raised by the Scottish Neurosciences Council regarding the use of the Canadian Criteria’.2
The Scottish Neurosciences Council published a forthright response to the SGPS draft advising specific concerns regarding adopting the Canadian consensus document.
They state ‘The Scottish Neuroscience Council takes the view that the ‘hard’ neurological signs of ataxia or fasciculations never occur in ME. Where these signs do occur, they have very specific clinical implications’.7
The Council warn that ‘There is a strong concern that by including these symptoms and signs in its core description of the condition, the statement would lead to misdiagnosis, both of those with ME-CFS and with other unrelated serious neurological diseases’.7
Owing to this, the Scottish Good Medical Practice working group revised their report, which now states that ‘neurological examination should be carried out to exclude specific neurological abnormalities such as: obvious muscle wasting, ptosis, upper motor neurone signs, ataxia, fasciculations, absent reflexes. If any of these abnormalities are present, neurological specialist referral is indicated. Muscle twitches and spasms occur and weakness is also common in ME-CFS because of pain and fatigue, but normal power is usually possible even if only for a few seconds’.8 They also describe objective neurological signs as a ‘red flag’, having alternative diagnostic implications.
The SGPS have not in fact endorsed the use of any particular criteria for diagnosing ME/CFS, and in reference to the Canadian criteria they only state that ‘When the Canadian Consensus Document definition is used to assist the diagnosis and management of ME-CFS, clinicians should carefully adhere to this specific neurological referral recommendation’.8
It seems as though the SGPS, which is, as the ScotPHN Health Care Needs Assessment Group state themselves is the guiding document for current practice, have remained ambiguous regarding which criteria should be adopted in Scotland, for reasons that remain opaque. If the purpose was to please patient groups who strongly supported the view that ME/CFS was neurological, this has been negated with the caveat that neurological signs are not indeed recognised as part of CFS or ME. This is the view of most neurologists: in a 2011 survey of neurologists working in the UK, 84% did not consider that ME or CFS was a neurological condition.9
If one accepts, as most neurologists do, that some of the signs and symptoms that are held by the Canadian consensus criteria to be incompatible with a diagnosis of ME/CFS, then the adoption of those same criteria by the ScotPHN Health Care Needs Assessment Group encourages poor practice and would, if implemented, have a detrimental impact on patient care.
It is clear that there is strong support from some quarters for the adoption of the Canadian criteria—a vote for example of members of the ME Association supported this, against the advice of their own medical advisor. Indeed, the Canadian criteria have become a litmus test among some sections of the patient community—if you are for it, you are supporting a neurological or neuroimmune view of the illness, and if you are against it, you must be in favour of a psychological/psychiatric view. But this is not a matter of opinion, preference or politics.
Either fasciculations are compatible with a diagnosis of ME/CFS or they are not. Attempting to synthesise patient views into the discourse regarding which criteria should be used to identify patients clinically has led to dangerous criteria being adopted, which increases the risk of misdiagnosis with all that might imply. Even if this is supported by the majority of those who make their voices heard on this issue, it still may not be in the interests of the majority or indeed entirety of all patients.
We took a straw poll of the members of two lists of multiprofessional NHS clinicians who regularly see ME/CFS patients and probably represent the majority of NHS professionals active in the field, and only a handful could recall any patients who had raised the issue of the Canadian guidelines or showed any interest in the subject. It seems not to be an issue for the majority of ME/CFS sufferers receiving treatment within the NHS.ii
continues...
There is more to read and I think it is important - if we had had time - to try and address some of these issues. Because the IOM committee will I am sure take such criticisms into account. And not all of them are without merit I don't believe.
However, whilst I think at the end of the day, the IOM are more likely to return a definition and written language more akin to the NICE Guideline (which is not all bad in my opinion), I still think the CCC personally is worth fighting for; but I also think there are aspects to it that could have been better addressed over all of these years: namely taking it into the field and validating it as a clinical definition and overcoming these objections.
If we had had the time and the ability, this kind of critique of our criteria/definitions would have been something worth doing ourselves I think. We need to acknowledge the weaknesses as well as champion the strengths and science and medicine simply have fallen short of doing the business and will continue to do so until such time as clear biomarkers can be established and we really know what we are dealing with. A critical appraisal of all the definitions/criteria/research would have been ideal - but as patients we can only do so much and I am out of my depth...